
<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>Lead Optimization</title>
  <link rel="stylesheet" href="styles.css" />
</head>
<body>
  <header><h1>Lead Optimization</h1></header>
  <nav><a href="index.html">Back to Home</a></nav>

  <main>
    <section>
      <h2>What is Lead Optimization?</h2>
      <p>Lead optimization is the process of refining hit compounds to improve their pharmacological properties, efficacy, selectivity, and safety. It bridges the gap between hit discovery and preclinical development, transforming promising molecules into viable drug candidates.</p>
    </section>

    <section>
      <h2>Basic Concepts</h2>
      <ul>
        <li><strong>Lead Compound:</strong> A molecule with confirmed activity and potential for development.</li>
        <li><strong>Optimization Goals:</strong> Enhance potency, selectivity, bioavailability, and reduce toxicity.</li>
        <li><strong>Structure-Activity Relationship (SAR):</strong> Understanding how chemical modifications affect biological activity.</li>
      </ul>
    </section>

    <section>
      <h2>Medicinal Chemistry Strategies</h2>
      <ul>
        <li>Functional group modifications</li>
        <li>Isosteric replacements</li>
        <li>Scaffold hopping</li>
        <li>Prodrug design</li>
        <li>Chirality and stereochemistry optimization</li>
      </ul>
    </section>

    <section>
      <h2>ADMET Profiling</h2>
      <ul>
        <li><strong>Absorption:</strong> Oral bioavailability, permeability (Caco-2, PAMPA)</li>
        <li><strong>Distribution:</strong> Plasma protein binding, tissue penetration</li>
        <li><strong>Metabolism:</strong> CYP450 interactions, metabolic stability</li>
        <li><strong>Excretion:</strong> Renal and hepatic clearance</li>
        <li><strong>Toxicity:</strong> hERG inhibition, genotoxicity, hepatotoxicity</li>
      </ul>
    </section>

    <section>
      <h2>Technologies and Tools</h2>
      <ul>
        <li>Computational modeling and QSAR</li>
        <li>High-content screening</li>
        <li>In vitro ADMET assays</li>
        <li>Mass spectrometry and NMR for metabolite profiling</li>
        <li>Machine learning for predictive toxicology</li>
      </ul>
    </section>

    <section>
      <h2>Challenges in Lead Optimization</h2>
      <ul>
        <li>Balancing potency with safety</li>
        <li>Metabolic liabilities and reactive metabolites</li>
        <li>Species differences in metabolism</li>
        <li>Complexity of multi-target optimization</li>
        <li>Time and resource constraints</li>
      </ul>
    </section>

    <section>
      <h2>Real-World Examples</h2>
      <ul>
        <li><strong>Statins:</strong> Optimization of HMG-CoA reductase inhibitors for lipid lowering</li>
        <li><strong>HIV protease inhibitors:</strong> Improved potency and resistance profiles</li>
        <li><strong>EGFR inhibitors:</strong> Enhanced selectivity for cancer therapy</li>
      </ul>
    </section>

    <section>
      <h2>Future Directions</h2>
      <ul>
        <li>AI-driven lead optimization and de novo design</li>
        <li>Integration of organ-on-chip models for ADMET testing</li>
        <li>Green chemistry approaches for sustainable synthesis</li>
        <li>Personalized lead optimization based on patient genomics</li>
      </ul>
    </section>
  </main>

  <footer><p>&copy; 2025 Drug Discovery Knowledge Base</p></footer>
</body>
</html>
